Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug
- Posted on July 25, 2025
- By South China Morning Post
- 1 Views
Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug
Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity investment in 3SBio.
